Oncology Biosimilars Market Report

Europe Oncology Biosimilars Market Size, Status and Forecast 2014-2026

  • POSTDATE：Jun 21, 2020
  • PAGES：168
  • REPORT CODE：GMM570982
  • REPORT SUMMARY
  • TABLE OF CONTENTS

  • The Oncology Biosimilars market was valued at XX.0 Million US$ in 2018 and is projected to reach XX.0 Million US$ by 2026, at a CAGR (Compound Annual Growth Rate) of 3.5% during the forecast period. Focusing on the Europe market, this report analyzes the specific consumption structure, such as types and end users. In order to present the status of the circulation of this product in different Europe countries, this report covers top export and import countries to confirm the potential markets. Leading countries such as Germany, UK, France, Italy, Spain, Poland, Russia, Switzerland, Turkey, Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden), Benelux (Belgium, Netherlands, and Luxembourg), Baltic States (Estonia, Latvia, and Lithuania) and other countries, the market status and consumption potential of these countries are covered in the research, providing valuable opinions of strategic adjustments for existing groups and new entrants.

    The Snapshot of Europe Oncology Biosimilars Market Segmentations:

    By Player:

    • Biocon

    • BIOCAD

    • Teva Pharmaceutical Industries Ltd

    • Sandoz International GmbH

    • STADA Arzneimittel AG

    By Type:

    • G-CSF

    • Hematopoietic Agents

    • Monoclonal Antibodies

    By End-User:

    • Retail Pharmacies

    • Hospital Pharmacies

    • Online Pharmacies

    By Region:

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Poland

    • Russia

    • Switzerland

    • Turkey

    • Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden)

      • Denmark

      • Finland

      • Norway

      • Sweden

      • Iceland

    • Benelux (Belgium, Netherlands, and Luxembourg)

      • Belgium

      • Netherlands

      • Luxembourg

    • Baltic States (Estonia, Latvia, and Lithuania)

      • Estonia

      • Latvia

      • Lithuania

  • Table of Contents

    1 Report Overview

    • 1.1 Product Definition and Scope

    • 1.2 PEST (Political, Economic, Social and Technological) Analysis of Oncology Biosimilars Market

    • 1.3 Market Segment by Type

    • 1.3.1 Europe Oncology Biosimilars Market Size and Growth Rate of G-CSF from 2014 to 2026

    • 1.3.2 Europe Oncology Biosimilars Market Size and Growth Rate of Hematopoietic Agents from 2014 to 2026

    • 1.3.3 Europe Oncology Biosimilars Market Size and Growth Rate of Monoclonal Antibodies from 2014 to 2026

    • 1.4 Market Segment by Application

    • 1.4.1 Europe Oncology Biosimilars Market Size and Growth Rate of Retail Pharmacies from 2014 to 2026

    • 1.4.2 Europe Oncology Biosimilars Market Size and Growth Rate of Hospital Pharmacies from 2014 to 2026

    • 1.4.3 Europe Oncology Biosimilars Market Size and Growth Rate of Online Pharmacies from 2014 to 2026

    • 1.5 Market Segment by Regions

      • 1.5.1 Germany Oncology Biosimilars Market Size and Growth Rate from 2014 to 2026

      • 1.5.2 UK Oncology Biosimilars Market Size and Growth Rate from 2014 to 2026

      • 1.5.3 France Oncology Biosimilars Market Size and Growth Rate from 2014 to 2026

      • 1.5.4 Italy Oncology Biosimilars Market Size and Growth Rate from 2014 to 2026

      • 1.5.5 Spain Oncology Biosimilars Market Size and Growth Rate from 2014 to 2026

      • 1.5.6 Poland Oncology Biosimilars Market Size and Growth Rate from 2014 to 2026

      • 1.5.7 Russia Oncology Biosimilars Market Size and Growth Rate from 2014 to 2026

      • 1.5.8 Switzerland Oncology Biosimilars Market Size and Growth Rate from 2014 to 2026

      • 1.5.9 Turkey Oncology Biosimilars Market Size and Growth Rate from 2014 to 2026

      • 1.5.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Oncology Biosimilars Market Size and Growth Rate from 2014 to 2026

      • 1.5.11 Benelux (Belgium, Netherlands, and Luxembourg) Oncology Biosimilars Market Size and Growth Rate from 2014 to 2026

      • 1.5.12 Baltic States (Estonia, Latvia, and Lithuania) Oncology Biosimilars Market Size and Growth Rate from 2014 to 2026

    2 Market Trends and Competitive Landscape

    • 2.1 Market Trends and Dynamics

      • 2.1.1 Market Challenges and Restraints

      • 2.1.2 Market Opportunities and Potentials

      • 2.1.3 Mergers and Acquisitions

    • 2.2 Competitive Landscape Analysis

      • 2.2.1 Industrial Concentration Analysis

      • 2.2.2 Porter's Five Forces Analysis of the Industry

      • 2.2.3 SWOT Analysis for New Entrants

    3 Segmentation of Oncology Biosimilars Market by Types

    • 3.1 Products Development Trends of Different Types

    • 3.2 Commercial Products Types of Major Venders

    • 3.3 Competitive Landscape Analysis of Different Types

    • 3.4 Market Size of Oncology Biosimilars by Major Types

      • 3.4.1 Market Size and Growth Rate of G-CSF

      • 3.4.2 Market Size and Growth Rate of Hematopoietic Agents

      • 3.4.3 Market Size and Growth Rate of Monoclonal Antibodies

    4 Segmentation of Oncology Biosimilars Market by End-Users

    • 4.1 Downstream Client Analysis by End-Users

    • 4.2 Competitive Landscape Analysis of Different End-Users

    • 4.3 Market Potential Analysis of Different End-Users

    • 4.4 Market Size of Oncology Biosimilars by Major End-Users

      • 4.4.1 Market Size and Growth Rate of Retail Pharmacies for Construction

      • 4.4.2 Market Size and Growth Rate of Hospital Pharmacies for Construction

      • 4.4.3 Market Size and Growth Rate of Online Pharmacies for Construction

    5 Market Analysis by Major Regions

    • 5.1 Europe Oncology Biosimilars Production Analysis by Top Regions

    • 5.2 Europe Oncology Biosimilars Consumption Analysis by Top Regions

    • 5.3 Europe Oncology Biosimilars Production, Import, Consumption and Export Analysis by Regions

      • 5.3.1 Germany Oncology Biosimilars Production, Import, Consumption and Export Analysis

      • 5.3.2 UK Oncology Biosimilars Production, Import, Consumption and Export Analysis

      • 5.3.3 France Oncology Biosimilars Production, Import, Consumption and Export Analysis

      • 5.3.4 Italy Oncology Biosimilars Production, Import, Consumption and Export Analysis

      • 5.3.5 Spain Oncology Biosimilars Production, Import, Consumption and Export Analysis

      • 5.3.6 Poland Oncology Biosimilars Production, Import, Consumption and Export Analysis

      • 5.3.7 Russia Oncology Biosimilars Production, Import, Consumption and Export Analysis

      • 5.3.8 Switzerland Oncology Biosimilars Production, Import, Consumption and Export Analysis

      • 5.3.9 Turkey Oncology Biosimilars Production, Import, Consumption and Export Analysis

      • 5.3.10 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Oncology Biosimilars Production, Import, Consumption and Export Analysis

      • 5.3.11 Benelux (Belgium, Netherlands, and Luxembourg) Oncology Biosimilars Production, Import, Consumption and Export Analysis

      • 5.3.12 Baltic States (Estonia, Latvia, and Lithuania) Oncology Biosimilars Production, Import, Consumption and Export Analysis

    6 Product Circulation of Oncology Biosimilars Market among Top Countries

    • 6.1 Top 5 Export Countries in Oncology Biosimilars Market from 2014 to 2019

      • 6.1.1 Top 5 Export Countries’ Export Value Analysis in Oncology Biosimilars Market from 2014 to 2019

      • 6.1.2 Top 5 Export Countries’ Export Volume Analysis in Oncology Biosimilars Market from 2014 to 2019

    • 6.2 Top 5 Import Countries in Oncology Biosimilars Market from 2014 to 2019

      • 6.2.1 Top 5 Import Countries’ Import Value Analysis in Oncology Biosimilars Market from 2014 to 2019

      • 6.2.2 Top 5 Import Countries’ Import Volume Analysis in Oncology Biosimilars Market from 2014 to 2019

    • 6.3 Emerging Top 3 Export Countries Analysis

    • 6.4 Emerging Top 3 Import Countries Analysis

    7. Germany Oncology Biosimilars Landscape Analysis

    • 7.1 Germany Oncology Biosimilars Landscape Analysis by Major Types

    • 7.2 Germany Oncology Biosimilars Landscape Analysis by Major End-Users

    8. UK Oncology Biosimilars Landscape Analysis

    • 8.1 UK Oncology Biosimilars Landscape Analysis by Major Types

    • 8.2 UK Oncology Biosimilars Landscape Analysis by Major End-Users

    9. France Oncology Biosimilars Landscape Analysis

    • 9.1 France Oncology Biosimilars Landscape Analysis by Major Types

    • 9.2 France Oncology Biosimilars Landscape Analysis by Major End-Users

    10. Italy Oncology Biosimilars Landscape Analysis

    • 10.1 Italy Oncology Biosimilars Landscape Analysis by Major Types

    • 10.2 Italy Oncology Biosimilars Landscape Analysis by Major End-Users

    11. Spain Oncology Biosimilars Landscape Analysis

    • 11.1 Spain Oncology Biosimilars Landscape Analysis by Major Types

    • 11.2 Spain Oncology Biosimilars Landscape Analysis by Major End-Users

    12. Poland Oncology Biosimilars Landscape Analysis

    • 12.1 Poland Oncology Biosimilars Landscape Analysis by Major Types

    • 12.2 Poland Oncology Biosimilars Landscape Analysis by Major End-Users

    13. Russia Oncology Biosimilars Landscape Analysis

    • 13.1 Russia Oncology Biosimilars Landscape Analysis by Major Types

    • 13.2 Russia Oncology Biosimilars Landscape Analysis by Major End-Users

    14. Switzerland Oncology Biosimilars Landscape Analysis

    • 14.1 Switzerland Oncology Biosimilars Landscape Analysis by Major Types

    • 14.2 Switzerland Oncology Biosimilars Landscape Analysis by Major End-Users

    15. Turkey Oncology Biosimilars Landscape Analysis

    • 15.1 Turkey Oncology Biosimilars Landscape Analysis by Major Types

    • 15.2 Turkey Oncology Biosimilars Landscape Analysis by Major End-Users

    16. Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Oncology Biosimilars Landscape Analysis

    • 16.1 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Oncology Biosimilars Landscape Analysis by Major Types

    • 16.2 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Oncology Biosimilars Landscape Analysis by Major End-Users

    • 16.3 Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Oncology Biosimilars Landscape Analysis by Top Countries

      • 16.3.1 Denmark Oncology Biosimilars Market Volume and Growth Rate

      • 16.3.2 Finland Oncology Biosimilars Market Volume and Growth Rate

      • 16.3.3 Norway Oncology Biosimilars Market Volume and Growth Rate

      • 16.3.4 Sweden Oncology Biosimilars Market Volume and Growth Rate

      • 16.3.6 Iceland Oncology Biosimilars Market Volume and Growth Rate

    17 Benelux (Belgium, Netherlands, and Luxembourg) Oncology Biosimilars Landscape Analysis

    • 17.1 Benelux (Belgium, Netherlands, and Luxembourg) Oncology Biosimilars Landscape Analysis by Major Types

    • 17.2 Benelux (Belgium, Netherlands, and Luxembourg) Oncology Biosimilars Landscape Analysis by Major End-Users

    • 17.3 Benelux (Belgium, Netherlands, and Luxembourg) Oncology Biosimilars Landscape Analysis by Top Countries

      • 17.3.1 Belgium Oncology Biosimilars Market Volume and Growth Rate

      • 17.3.2 Netherlands Oncology Biosimilars Market Volume and Growth Rate

      • 17.3.3 Luxembourg Oncology Biosimilars Market Volume and Growth Rate

    18 Baltic States (Estonia, Latvia, and Lithuania) Oncology Biosimilars Landscape Analysis

    • 18.1 Baltic States (Estonia, Latvia, and Lithuania) Oncology Biosimilars Landscape Analysis by Major Types

    • 18.2 Baltic States (Estonia, Latvia, and Lithuania) Oncology Biosimilars Landscape Analysis by Major End-Users

    • 18.3 Baltic States (Estonia, Latvia, and Lithuania) Oncology Biosimilars Landscape Analysis by Top Countries

      • 18.3.1 Estonia Oncology Biosimilars Market Volume and Growth Rate

      • 18.3.2 Latvia Oncology Biosimilars Market Volume and Growth Rate

      • 18.3.3 Lithuania Oncology Biosimilars Market Volume and Growth Rate

    19 Major Players Profiles

    • 19.1 Biocon

      • 19.1.1 Biocon Company Profile and Development Status

      • 19.1.2 Market Performance

      • 19.1.3 Product and Service Introduction

    • 19.2 BIOCAD

      • 19.2.1 BIOCAD Company Profile and Development Status

      • 19.2.2 Market Performance

      • 19.2.3 Product and Service Introduction

    • 19.3 Teva Pharmaceutical Industries Ltd

      • 19.3.1 Teva Pharmaceutical Industries Ltd Company Profile and Development Status

      • 19.3.2 Market Performance

      • 19.3.3 Product and Service Introduction

    • 19.4 Sandoz International GmbH

      • 19.4.1 Sandoz International GmbH Company Profile and Development Status

      • 19.4.2 Market Performance

      • 19.4.3 Product and Service Introduction

    • 19.5 STADA Arzneimittel AG

      • 19.5.1 STADA Arzneimittel AG Company Profile and Development Status

      • 19.5.2 Market Performance

      • 19.5.3 Product and Service Introduction

    The List of Tables and Figures (Totals 118 Figures and 165 Tables)

    • Figure Product Picture

    • Figure Oncology Biosimilars Market Size and Growth Rate of G-CSF Market, 2015 - 2026 (USD Million)

    • Figure Oncology Biosimilars Market Size and Growth Rate of Hematopoietic Agents Market, 2015 - 2026 (USD Million)

    • Figure Oncology Biosimilars Market Size and Growth Rate of Monoclonal Antibodies Market, 2015 - 2026 (USD Million)

    • Figure Oncology Biosimilars Market Size and Growth Rate of Retail Pharmacies from 2014 to 2026

    • Figure Oncology Biosimilars Market Size and Growth Rate of Hospital Pharmacies from 2014 to 2026

    • Figure Oncology Biosimilars Market Size and Growth Rate of Online Pharmacies from 2014 to 2026

    • Figure Germany Oncology Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure UK Oncology Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure France Oncology Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Italy Oncology Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Spain Oncology Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Poland Oncology Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Russia Oncology Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Switzerland Oncology Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Turkey Oncology Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Canada Oncology Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Mexico Oncology Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Oncology Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Denmark Oncology Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Finland Oncology Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Norway Oncology Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Sweden Oncology Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Iceland Oncology Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Benelux (Belgium, Netherlands, and Luxembourg) Oncology Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Belgium Oncology Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Netherlands Oncology Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Luxembourg Oncology Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Baltic States (Estonia, Latvia, and Lithuania) Oncology Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Estonia Oncology Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Latvia Oncology Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Lithuania Oncology Biosimilars Market Size and Growth Rate from 2014 to 2026

    • Figure Development Trends and Industry Dynamics of Oncology Biosimilars Industry

    • Figure Market Challenges and Restraints

    • Figure Market Opportunities and Potentials

    • Table Mergers and Acquisition

    • Figure Market Share of TOP 6 Players from 2014 to 2019

    • Figure Porter's Five Forces Analysis

    • Figure New Entrant SWOT Analysis

    • Table Specifications of Different Types of Oncology Biosimilars

    • Figure Development Trends of Different Types

    • Table Commercial Products Types of Major Vendors

    • Figure Competitive Landscape Analysis of Different Types

    • Table Consumption of Oncology Biosimilars by Different Types from 2014 to 2026

    • Table Consumption Share of Oncology Biosimilars by Different Types from 2014 to 2026

    • Figure Oncology Biosimilars Market Size and Growth Rate of G-CSF Market, 2015 - 2026 (USD Million)

    • Figure Oncology Biosimilars Market Size and Growth Rate of Hematopoietic Agents Market, 2015 - 2026 (USD Million)

    • Figure Oncology Biosimilars Market Size and Growth Rate of Monoclonal Antibodies Market, 2015 - 2026 (USD Million)

    • Table Downstream Client Analysis by End-Users

    • Figure Competitive Landscape Analysis of Different End-Users

    • Table Market Potential Analysis of Different End-Users

    • Table Consumption of Oncology Biosimilars by Different End-Users from 2014 to 2026

    • Table Consumption Share of Oncology Biosimilars by Different End-Users from 2014 to 2026

    • Figure Oncology Biosimilars Market Size and Growth Rate of Retail Pharmacies from 2014 to 2026

    • Figure Oncology Biosimilars Market Size and Growth Rate of Hospital Pharmacies from 2014 to 2026

    • Figure Oncology Biosimilars Market Size and Growth Rate of Online Pharmacies from 2014 to 2026

    • Table Europe Oncology Biosimilars Production by Major Regions

    • Table Europe Oncology Biosimilars Production Share by Major Regions

    • Figure Europe Oncology Biosimilars Production Share by Major Countries and Regions in 2014

    • Table Europe Oncology Biosimilars Consumption by Major Regions

    • Table Europe Oncology Biosimilars Consumption Share by Major Regions

    • Table Germany Oncology Biosimilars Production, Import, Consumption and Export Analysis

    • Table UK Oncology Biosimilars Production, Import, Consumption and Export Analysis

    • Table France Oncology Biosimilars Production, Import, Consumption and Export Analysis

    • Table Italy Oncology Biosimilars Production, Import, Consumption and Export Analysis

    • Table Spain Oncology Biosimilars Production, Import, Consumption and Export Analysis

    • Table Poland Oncology Biosimilars Production, Import, Consumption and Export Analysis

    • Table Russia Oncology Biosimilars Production, Import, Consumption and Export Analysis

    • Table Switzerland Oncology Biosimilars Production, Import, Consumption and Export Analysis

    • Table Turkey Oncology Biosimilars Production, Import, Consumption and Export Analysis

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Oncology Biosimilars Production, Import, Consumption and Export Analysis

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Oncology Biosimilars Production, Import, Consumption and Export Analysis

    • Table Baltic States (Estonia, Latvia, and Lithuania) Oncology Biosimilars Production, Import, Consumption and Export Analysis

    • Table Top 5 Export Countries' Export Value Analysis in Oncology Biosimilars Market from 2014 to 2019

    • Table Top 5 Export Countries' Export Volume Analysis in Oncology Biosimilars Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Value Analysis in Oncology Biosimilars Market from 2014 to 2019

    • Table Top 5 Import Countries' Import Volume Analysis in Oncology Biosimilars Market from 2014 to 2019

    • Figure Emerging Top 3 Export Countries Analysis

    • Figure Emerging Top 3 Import Countries Analysis

    • Table Germany Oncology Biosimilars Consumption by Types from 2014 to 2026

    • Table Germany Oncology Biosimilars Consumption Share by Types from 2014 to 2026

    • Table Germany Oncology Biosimilars Consumption by End-Users from 2014 to 2026

    • Table Germany Oncology Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table UK Oncology Biosimilars Consumption by Types from 2014 to 2026

    • Table UK Oncology Biosimilars Consumption Share by Types from 2014 to 2026

    • Table UK Oncology Biosimilars Consumption by End-Users from 2014 to 2026

    • Table UK Oncology Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table France Oncology Biosimilars Consumption by Types from 2014 to 2026

    • Table France Oncology Biosimilars Consumption Share by Types from 2014 to 2026

    • Table France Oncology Biosimilars Consumption by End-Users from 2014 to 2026

    • Table France Oncology Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table Italy Oncology Biosimilars Consumption by Types from 2014 to 2026

    • Table Italy Oncology Biosimilars Consumption Share by Types from 2014 to 2026

    • Table Italy Oncology Biosimilars Consumption by End-Users from 2014 to 2026

    • Table Italy Oncology Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table Spain Oncology Biosimilars Consumption by Types from 2014 to 2026

    • Table Spain Oncology Biosimilars Consumption Share by Types from 2014 to 2026

    • Table Spain Oncology Biosimilars Consumption by End-Users from 2014 to 2026

    • Table Spain Oncology Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table Poland Oncology Biosimilars Consumption by Types from 2014 to 2026

    • Table Poland Oncology Biosimilars Consumption Share by Types from 2014 to 2026

    • Table Poland Oncology Biosimilars Consumption by End-Users from 2014 to 2026

    • Table Poland Oncology Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table Russia Oncology Biosimilars Consumption by Types from 2014 to 2026

    • Table Russia Oncology Biosimilars Consumption Share by Types from 2014 to 2026

    • Table Russia Oncology Biosimilars Consumption by End-Users from 2014 to 2026

    • Table Russia Oncology Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table Switzerland Oncology Biosimilars Consumption by Types from 2014 to 2026

    • Table Switzerland Oncology Biosimilars Consumption Share by Types from 2014 to 2026

    • Table Switzerland Oncology Biosimilars Consumption by End-Users from 2014 to 2026

    • Table Switzerland Oncology Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table Turkey Oncology Biosimilars Consumption by Types from 2014 to 2026

    • Table Turkey Oncology Biosimilars Consumption Share by Types from 2014 to 2026

    • Table Turkey Oncology Biosimilars Consumption by End-Users from 2014 to 2026

    • Table Turkey Oncology Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Oncology Biosimilars Consumption by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Oncology Biosimilars Consumption Share by Types from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Oncology Biosimilars Consumption by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Oncology Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Oncology Biosimilars Consumption by Major Countries from 2014 to 2026

    • Table Nordic Countries (Denmark, Finland, Iceland, Norway and Sweden) Oncology Biosimilars Consumption Share by Major Countries from 2014 to 2026

    • Figure Denmark Oncology Biosimilars Market Volume and Growth Rate from 2014 to 2026

    • Figure Finland Oncology Biosimilars Market Volume and Growth Rate from 2014 to 2026

    • Figure Norway Oncology Biosimilars Market Volume and Growth Rate from 2014 to 2026

    • Figure Sweden Oncology Biosimilars Market Volume and Growth Rate from 2014 to 2026

    • Figure Iceland Oncology Biosimilars Market Volume and Growth Rate from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Oncology Biosimilars Consumption by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Oncology Biosimilars Consumption Share by Types from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Oncology Biosimilars Consumption by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Oncology Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Oncology Biosimilars Consumption by Major Countries from 2014 to 2026

    • Table Benelux (Belgium, Netherlands, and Luxembourg) Oncology Biosimilars Consumption Share by Major Countries from 2014 to 2026

    • Figure Belgium Oncology Biosimilars Market Volume and Growth Rate from 2014 to 2026

    • Figure Netherlands Oncology Biosimilars Market Volume and Growth Rate from 2014 to 2026

    • Figure Luxembourg Oncology Biosimilars Market Volume and Growth Rate from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Oncology Biosimilars Consumption by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Oncology Biosimilars Consumption Share by Types from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Oncology Biosimilars Consumption by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Oncology Biosimilars Consumption Share by End-Users from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Oncology Biosimilars Consumption by Major Countries from 2014 to 2026

    • Table Baltic States (Estonia, Latvia, and Lithuania) Oncology Biosimilars Consumption Share by Major Countries from 2014 to 2026

    • Figure Estonia Oncology Biosimilars Market Volume and Growth Rate from 2014 to 2026

    • Figure Latvia Oncology Biosimilars Market Volume and Growth Rate from 2014 to 2026

    • Figure Lithuania Countries Oncology Biosimilars Market Volume and Growth Rate from 2014 to 2026

    • Table Biocon Profiles

    • Table Biocon Production, Value, Price, Gross Margin 2014-2019

    • Table Biocon Product benchmarking

    • Table Biocon Strategic initiatives

    • Table Biocon SWOT analysis

    • Table BIOCAD Profiles

    • Table BIOCAD Production, Value, Price, Gross Margin 2014-2019

    • Table BIOCAD Product benchmarking

    • Table BIOCAD Strategic initiatives

    • Table BIOCAD SWOT analysis

    • Table Teva Pharmaceutical Industries Ltd Profiles

    • Table Teva Pharmaceutical Industries Ltd Production, Value, Price, Gross Margin 2014-2019

    • Table Teva Pharmaceutical Industries Ltd Product benchmarking

    • Table Teva Pharmaceutical Industries Ltd Strategic initiatives

    • Table Teva Pharmaceutical Industries Ltd SWOT analysis

    • Table Sandoz International GmbH Profiles

    • Table Sandoz International GmbH Production, Value, Price, Gross Margin 2014-2019

    • Table Sandoz International GmbH Product benchmarking

    • Table Sandoz International GmbH Strategic initiatives

    • Table Sandoz International GmbH SWOT analysis

    • Table STADA Arzneimittel AG Profiles

    • Table STADA Arzneimittel AG Production, Value, Price, Gross Margin 2014-2019

    • Table STADA Arzneimittel AG Product benchmarking

    • Table STADA Arzneimittel AG Strategic initiatives

    • Table STADA Arzneimittel AG SWOT analysis

Report Version Choose

Report

BUY NOW

Our Customers

Beyond grateful for the confidence and support from all partners and customers.A win-win situation is our ultimate pursuit.

Beyond Consulting, Future is Feasible

We provide more professional and intelligent market reports to complement your business decisions.

CONTACT US